Research Article
Potential Synergy Activity of the Novel Ceragenin, CSA-13, against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Bacteremia Patients
Table 1
Comparative in vitro activity of antimicrobial agents against 60 isolates of A. baumannii.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLSI breakpoints for susceptible and resistant to colistin ≤2 mg/L and ≥4 mg/L; tobramycin ≤4 mg/L and ≥16 mg/L; ciprofloxacin ≤1 mg/L and ≥4 mg/L and meropenem ≤4 mg/L and ≥16 mg/L, respectively. bM.S.: moderately susceptible. |